Table 2.

Description of the knowledge scale items’ responses.

Monkeypox Knowledge Items	No	I Do Not Know	Yes
MPOX is prevalent in the Middle East	268 (41.5%)	110 (17.0%)	268 (41.5%)
MPOX is prevalent in Western and Central Africa	58 (9.0%)	88 (13.6%)	500 (77.4%)
There is an outbreak of human MPOX in the world	137 (21.2%)	89 (13.8%)	420 (65.0%)
MPOX is caused by a virus	66 (10.2%)	56 (8.7%)	524 (81.1%)
Human-to-human transmission of MPOX occurs through skin-to-skin contact	49 (7.6%)	41 (6.3%)	556 (86.1%)
Human-to-human transmission of MPOX occurs through touching objects or surfaces that have been used by someone with MPOX	109 (16.9%)	60 (9.3%)	477 (73.8%)
Human-to-human transmission of MPOX occurs through contact with respiratory secretions	112 (17.3%)	200 (31.0%)	334 (51.7%)
MPOX and smallpox have similar signs and symptoms	123 (19.0%)	107 (16.6%)	416 (64.4%)
Skin rash is one of the signs or symptoms of human MPOX	52 (8.0%)	52 (8.0%)	542 (83.9%)
Pustule is one of the signs or symptoms of human MPOX	115 (17.8%)	70 (10.8%)	461 (71.4%)
Antibiotics are used to treat human MPOX	168 (26.0%)	118 (18.3%)	360 (55.7%)
Diarrhea is one of the signs or symptoms of human MPOX	222 (24.4%)	158 (24.5%)	266 (41.2%)
Vaccination is available to prevent human MPOX	206 (31.9%)	118 (18.3%)	322 (49.8%)
Who is at increased risk for severe MPOX disease?
Young children less than 8 years of age are at increased risk for severe MPOX disease	152 (23.5%)	54 (8.4%)	440 (68.1%)
Pregnant women are at increased risk for severe MPOX disease	170 (26.3%)	74 (11.5%)	402 (62.2%)
Immunocompromised patients are at increased risk for severe MPOX disease	94 (14.6%)	37 (5.7%)	515 (79.7%)
Individuals with a history of atopic dermatitis or eczema are at increased risk for severe MPOX disease	196 (30.3%)	86 (13.3%)	364 (56.3%)

Numbers in bold indicate correct responses; MPOX: monkeypox.